Biogen Inc. reported that its Phase 2 AMETHYST study of litifilimab, a humanized IgG1 monoclonal antibody targeting BDCA2, achieved a statistically significant 11.8 % greater reduction in cutaneous lupus activity versus placebo at week 16, as measured by the Cutaneous Lupus Activity Investigators’ Global Assessment Revised score. The data were presented at the American Academy of Dermatology Annual Meeting on Saturday, March 28, 2026, and represent a key milestone for the company’s lupus portfolio.
The study enrolled 59 patients, although other sources report 93 participants, indicating a discrepancy that has yet to be resolved. Litifilimab produced a rapid separation from placebo, with 40.8 % of patients achieving a CLASI‑50 response (≥ 50 % reduction in disease activity) by week 24 compared with 21 % on placebo. The primary endpoint was met at week 16, and the secondary endpoint of CLASI‑50 was also achieved, underscoring the drug’s efficacy in a disease with no approved targeted therapies.
Safety data were consistent with prior litifilimab studies. Most adverse events were mild to moderate, and the serious adverse event rate in the litifilimab arm was 6.8 %. The safety profile supports continued development and aligns with the expectations set by the drug’s mechanism of action, which blocks BDCA2 on plasmacytoid dendritic cells to reduce type I interferon production.
The positive Phase 2 results reinforce Biogen’s Breakthrough Therapy designation for litifilimab, granted earlier in 2026, and support the transition to the Phase 3 portion of the AMETHYST program. The data strengthen the company’s first‑in‑class positioning in cutaneous lupus, a market with high unmet need, and enhance Biogen’s competitive standing within its broader lupus strategy that includes other investigational agents such as dapirolizumab pegol and felzartamab.
Biogen’s senior leadership has highlighted the significance of these findings. The company’s senior vice president of the MS and Immunology Disease Units emphasized the importance of the lupus portfolio within Biogen’s broader rare‑disease strategy, while the chief medical officer expressed pride in the science behind litifilimab and its potential to advance understanding of cutaneous lupus. The results are expected to inform the company’s Phase 3 planning and future regulatory submissions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.